

Ref: EPL/CS/SE/0004/2025

Date: January 23, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Press Release

Please find enclosed herewith a Press Release titled "Emcure Pharmaceuticals Inaugurates World-class R&D centre in Gujarat".

You are requested to take the same on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

Press Release**Emcure Pharmaceuticals Inaugurates World-class R&D centre in Gujarat**

(Strengthens its commitment to advancing cutting edge research in complex drug delivery)

- *The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations.*
- *Emcure's ERC aims to drive breakthrough research and develop transformative therapies to enhance patient care*

Ahmedabad, Gujarat – January 23, 2025: Emcure Pharmaceuticals Limited, one of India's leading pharma companies announced the inauguration of its state-of-the-art Formulation Research and Development (R&D) Centre near Tapovan Circle, Ahmedabad. The Emcure Research Centre (ERC) is strategically designed to enable breakthroughs in complex drug delivery systems, such as sustained-release formulations, liposomal injections and advanced dermal therapies. The landmark facility was inaugurated by Hon'ble Minister of Health and Family Welfare, Gujarat, Shri. Rushikeshbhai Patel, in a ceremony that marks Emcure's commitment to advancing healthcare through cutting-edge research and transformative drug development.

The new ERC facility is designed to accelerate pharmaceutical innovation with state-of-the-art laboratories and advanced equipment for each of the dosage forms. From early-stage pre-formulation studies to scaling-up, the ERC seamlessly integrates all aspects of pharmaceutical development while adhering to global regulatory standards.

A team of 350 highly skilled professionals, including doctorate, post-graduate and graduate specializing in pharmaceutical sciences, bio-engineering, analytical chemistry, pharmacovigilance and regulatory affairs will work together to develop novel formulations, enhance drug bioavailability and create patient-centric delivery solutions.

Commenting on the occasion, **Shri Rushikeshbhai Patel, Honourable Minister of Health and Family Welfare, Government of Gujarat** said, "It gives me great pride to inaugurate Emcure Pharmaceuticals' advanced R&D center in Ahmedabad. Gujarat has always been a hub for innovation and progress, and this facility is a shining example of how we can create futuristic healthcare solutions. By investing in drug research and nurturing local talent, Emcure is not only contributing to Gujarat's growth but also strengthening India's position as a global leader in pharmaceuticals. I compliment the entire team at Emcure for this remarkable achievement".

With a focus on sustainable solutions and green chemistry practices, the Emcure Research Centre reflects the company's dedication to environmentally conscious innovations. It also serves as a catalyst for job creation and collaborations with academic institutions, industry experts and regulatory bodies, promoting an ecosystem of shared knowledge and growth.

"Over the past four decades, Emcure has remained steadfast in its commitment to pushing the boundaries of pharmaceutical research and development, creating innovative solutions for unmet medical challenges", said **Mr. Satish Mehta, Founder and CEO, Emcure Pharmaceuticals**. "This new R&D centre represents a significant milestone in our continued pursuit of innovation, by combining advanced research technology with a talented team. With a focus on both efficiency and quality, the centre is set to drive advancements that will reshape the future of medicine globally", he concluded.

By developing differentiated products for all regulated, emerging and domestic markets, ERC further solidifies Gujarat's status as a hub for pharmaceutical research.

About Emcure Pharmaceuticals Limited:

Emcure Pharmaceuticals Limited (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Media Contact Information

naveen.soni@emcure.com